Burde R, Buschauer A, Seifert R
Institut für Pharmakologie, Freie Universität Berlin.
Naunyn Schmiedebergs Arch Pharmacol. 1990 May;341(5):455-61. doi: 10.1007/BF00176340.
Human neutrophils possess an NADPH oxidase which catalyzes superoxide (O2-) formation and is activated by chemotactic peptides. Histamine inhibits O2- formation via H2-receptors (Burde et al. 1989). We characterized the neutrophil H2-receptor with a series of new guanidine-type H2-agonists structurally derived from impromidine. Histamine inhibited O2- formation with an IC50 value of 6.7 +/- 1.2 microM. Five aryloxy- and arylthioalkylguanidines were less potent and effective than histamine. Several arpromidine-like phenyl(pyridylalkyl)guanidines were either full or partial H2-agonists. Some guanidines possess a three-membered carbon chain connecting the aromatic rings and the guanidine group; they were similarly potent and effective as histamine. Shortening or elongation of the carbon chain substantially decreased the potency and intrinsic activity of the guanidines. Halogenation of the phenyl ring did not substantially affect the potency and intrinsic activity of the compounds in comparison to the non-substituted parent compound. The H2-antagonist, famotidine, competitively antagonized inhibition of O2- formation caused by the guanidine, arpromidine, with a pA2 value of 6.84. The H2-antagonist, cimetidine, differentially counteracted inhibition caused by partial and full H2-agonists. Partial H2-agonists antagonized the effects of histamine. The inhibitor of phosphodiesterases, 3-isobutyl-1-methylxanthine, additively enhanced the inhibitory effects of histamine and guanidines. The properties of the neutrophil H2-receptor were compared with literature data concerning properties of the H2-receptor of the guinea pig atrium. In the latter system, guanidines are full H2-agonists with potencies of up to 125-fold of that of histamine. Our data indicate that guanidines inhibit O2- formation in human neutrophils via H2-receptors.(ABSTRACT TRUNCATED AT 250 WORDS)
人类中性粒细胞拥有一种NADPH氧化酶,该酶催化超氧化物(O2-)的形成,并被趋化肽激活。组胺通过H2受体抑制O2-的形成(Burde等人,1989年)。我们用一系列结构上源自咪丁硫脲的新型胍类H2激动剂对中性粒细胞H2受体进行了表征。组胺抑制O2-形成的IC50值为6.7±1.2微摩尔。五种芳氧基和芳硫基烷基胍的效力和效果均低于组胺。几种类似阿普米定的苯基(吡啶基烷基)胍是完全或部分H2激动剂。一些胍具有连接芳环和胍基的三元碳链;它们的效力和效果与组胺相似。碳链的缩短或延长会大幅降低胍的效力和内在活性。与未取代的母体化合物相比,苯环的卤化对化合物的效力和内在活性没有实质性影响。H2拮抗剂法莫替丁竞争性拮抗胍阿普米定对O2-形成的抑制作用,pA2值为6.84。H2拮抗剂西咪替丁对部分和完全H2激动剂引起的抑制作用有不同的拮抗作用。部分H2激动剂拮抗组胺的作用。磷酸二酯酶抑制剂3-异丁基-1-甲基黄嘌呤可累加增强组胺和胍的抑制作用。将中性粒细胞H2受体的特性与豚鼠心房H2受体特性的文献数据进行了比较。在后者的系统中,胍是完全的H2激动剂,效力高达组胺的125倍。我们的数据表明,胍通过H2受体抑制人类中性粒细胞中O2-的形成。(摘要截短于250字)